在近期举行的美国基因与细胞治疗学会（ASGCT）年会上，Voyager Therapeutics公司公布了一项引人注目的最新研究数据。结果显示，其研究性疗法Vy1706在单次静脉注射后表现出良好的耐受性。更关键的是，为期三个月的良好实验室规范（GLP）毒理学研究数据表明，该疗法能够有效降低与阿尔茨海默病密切相关的Tau蛋白水平。
基于这些积极的临床前发现，公司计划进一步推进Vy1706的开发进程。针对阿尔茨海默病的首次人体临床试验，目前预计将于2026年下半年正式启动。这一进展标志着Voyager在神经退行性疾病治疗领域的探索迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.